Study of INR102 for advanced prostate cancer (Phase 1/2)
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new investigational drug called INR102 for prostate cancer that has spread and stopped responding to standard treatments. It's given by injection, and the study will check if it's safe and if it can shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and willing to sign a consent form.
- You have a confirmed type of prostate cancer that is PSMA-positive on a special scan.
- Your testosterone is kept very low (castrate level), but your cancer has still grown based on PSA tests, scans, or new bone spots.
- You have tried at least one newer hormone therapy (such as enzalutamide, apalutamide, or abiraterone) and a chemotherapy drug like docetaxel, and those treatments stopped working.
- Your cancer has spread to at least one other part of your body (metastases).
- Your blood counts, liver and kidney function, and overall health (ECOG 0-2) must meet certain minimum levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging agent (INR101) used with a PET/CT scan to help see prostate cancer before surgery. The scan may help doctors plan your prostate removal surgery more accurately.
This trial tests a new radioactive drug called 225Ac-LNC1011 for men with a specific type of advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if it can shrink tumors or slow the disease.
This trial tests an experimental drug, GLR2037, for men with advanced prostate cancer that has spread to the bones or soft tissue and has progressed despite prior treatments. The drug may help slow the cancer's growth.
This study tests a new experimental treatment for advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The treatment is a radioactive drug that targets a protein called PSMA on cancer cells, aiming to deliver radiation directly to the tumor.
This Phase 1 study tests how safe PRL-02 depot (an injection) is and finds the best dose for men with advanced prostate cancer. It may help determine a new treatment option for cancers that have spread or are getting worse despite standard care.
This early-stage trial tests a new drug called TRC003 for men with advanced prostate cancer that has spread and stopped responding to standard treatments. The drug is designed to target cancer cells that show a specific marker called PSMA.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.